Biomarkers in Atrial Fibrillation: Pathogenesis and Clinical Implications

Jean Jacques Noubiap, Prashanthan Sanders, Stanley Nattel, Dennis H. Lau

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Biomarkers derived from the key components of the pathophysiology of atrial fibrillation (AF) and its complications have the potential to play an important role in earlier characterization of AF phenotype and in risk prediction of adverse clinical events, which may translate into improved management strategies. C-reactive protein, natriuretic peptides, cardiac troponins, growth differentiation factor-15, and fibroblast growth factor-23 have been shown to be the most promising biomarkers in AF. Some biomarkers have already been included in clinical risk scores to predict postoperative AF, thromboembolism, major bleeding, and death. Considerably more work is needed to bring these novel biomarkers into routine clinical management of patients with AF.

Original languageEnglish
Pages (from-to)221-233
Number of pages13
JournalCardiac Electrophysiology Clinics
Issue number1
Publication statusPublished or Issued - 1 Mar 2021


  • Atrial fibrillation
  • Atrial fibrosis
  • BNP
  • Biomarkers
  • Inflammation
  • Oxidative stress
  • Stroke
  • Troponin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Medicine(all)

Cite this